Novo Nordisk
Ozempic and Wegovy pens will be available via GoodRx for $499 per month.
The announcement comes the same week the pharma giant ended its collaboration with Hims & Hers to sell Wegovy, alleging the company engages in deceptive marketing and illegally sells copycat drugs.
The partnership has been terminated less than two months after launch as Novo Nordisk alleges Hims & Hers is illegally selling copycat drugs and using deceptive marketing practices.
Americans with a prescription will have access to Novo Nordisk's obesity drug Wegovy through the Hims & Hers platform for $599 monthly.
Novo Nordisk is bringing its expertise in chronic disease management to Kakao's mobile diabetes app.
The partnership includes a patient support programme that brings tailored and age-based educational content to patients with Type 1 diabetes.
The integration is aimed at boosting data collection.
Novo Nordisk Pharma Ltd. and Health2Sync partner in Japan to expand digital diabetes management to …
Health2Sync and Novo Nordisk Pharma Ltd.
Abbott joins Dexcom, Glooko and Roche as a data-sharing partner for the as-yet-unlaunched device.
This morning Glooko also announced that its diasend platform will be compatible with the Dexcom G6.